5900-13-0

Basic information

• Product Name: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE
• Synonyms: 2-AMINO-5-BROMO-3-METHOXYPYRAZINE;5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE;5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE, 95+%;3-Methoxy-5-bromopyrazin-2-amine;5-Bromo-3-methoxy-2-pyrazinamine;2-Amino-5-Bromo-3-methoxypyrazin;5-BROMO-3-METHOXYPYR;5-bromo-3-methoxypyrazin-2-amine
• CAS NO: 5900-13-0
• Molecular Formula: C₅H₆BrN₃O
• Molecular Weight: 204.02
• Product Categories: amine|alkyl bromide
• Mol File: 5900-13-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: 138 ºC
• Boiling Point: 262 ºC
• Flash Point: 112 ºC
• Appearance: /
• Density: 1.723
• Vapor Pressure: 0.0113mmHg at 25°C
• Refractive Index: 1.
• Storage Temp.: 2-8°C
• Solubility: DMSO, Methanol
• PKA: 1.93±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE(5900-13-0)
• EPA Substance Registry System: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE(5900-13-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 5900-13-0(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

5-Bromo-3-methoxy-2-pyrazinamine is an intermediate in the preparation of N-pyrazinylbenzenesulfonamides used in treatment of chemokine mediated diseases such as asthma.

InChI:InChI=1/C5H6BrN3O/c1-10-5-4(7)8-2-3(6)9-5/h2H,1H3,(H2,7,8)

Upstream product

• 124-41-4 sodium methylate 
• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 67-56-1 methanol 
• 4774-10-1 2-amino-3-methoxypyrazine 
• 87444-39-1 5-bromo-3-methylsulfonylpyrazin-2-amine 

Downstream Products

• 144294-15-5 ethyl 6-bromo-8-methoxy-2-phenylimidazo<1,2-a>pyrazine-3-carboxylate 
• 94139-36-3 4-amino-N-(5-bromo-3-methoxy-pyrazin-2-yl)-benzenesulfonamide 
• 95516-10-2 4-acetylamino-N-(5-bromo-3-methoxy-pyrazin-2-yl)-benzenesulfonamide 
• 1608497-98-8 4-[(5-bromo-3-methoxypyrazin-2-yl)imino]-2,6-di-tert-butylcyclohexa-2,5-dien-1-one 

Relevant articles and documents

Synthesis and cytotoxicity evaluation of novel indolylpyrimidines and indolylpyrazines as potential antitumor agents

Novel indolylpyrimidines and indolylpyrazines have been synthesized as potential antitumor agents. They were screened in a panel of 60 human tumor cell lines in vitro. Compounds 7, 9, 10, 15, 21 exhibited efficiently cytotoxic activities with GI50 values in the low micromolar range against a variety of human cancer cell lines. 2,4-Bis(3′-indolyl)pyrimidine 8 displayed selective cytotoxic activity against IGROV1 tumor cell line with the GI50 value below 0.01 μM.

Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators

The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of Aβ42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting Aβ42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced Aβ42 levels in the plasma of J20 mice, in addition to reducing Aβ42 levels in the plasma and brain of Tg2576 mice.

Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists

N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high-throughput screen (HTS) of a subset of the AstraZeneca compound bank. As a hit with a lead-like profile, it was an excellent sta